UK drugs companies face disadvantage due to EMA Brexit approach

The European Medicines Agency’s (EMA’s) assumption that the UK will be a ‘third country’ after its withdrawal from the EU, and no longer part of the Europe-wide drugs safety monitoring system, would put UK-based drug companies at a disadvantage, a life sciences expert has said.